How much does a box of lorlatinib/lorlatinib cost?

Lorlatinib is a selective, brain-penetrating small molecule that competes with adenosine triphosphate for the binding of ALK and ROS1 tyrosine kinases. This mechanism of action solves the resistance mechanism after previous treatment with ALK inhibitors. Lorlatinib has been approved by Ministry of Health in multiple countries as monotherapy for patients withALK-positive locally advanced or metastatic non-small cell lung cancer. The recommended dose of lorlatinib is 100 mg once daily, continuously. Treatment with lorlatinib should be continued until disease progression or unacceptable toxicity.

A phase III, open-label, randomized superiority trial (CROWN) provides evidence on the efficacy and safety of lorlatinib as first-line treatment for adult patients with ALK-positive locally advanced (not suitable for curative treatment) or metastatic non-small cell lung cancer. Patients treated with lorlatinib showed a statistically significant improvement in PFS compared with crizotinib. Sustained improvement in PFS was observed in all patient subgroups evaluated, most notably in patients with brain metastases.

There is now an original drug on the domestic market Lorlatinib tablets, which has been included in the reimbursement scope of Class B medical insurance. Its common specifications include 25mg*90 tablets and 100mg*30 tablets, priced at about 20,000 yuan per box. Hong KongThe price of original research version of drugs is generally between 30,000 and 50,000 yuan, while the original research version imported from Türkiye costs about 10,000 yuan. In addition, lower-priced generic drugs are available on the market that have ingredients similar to the brand-name drugs. For example, a generic drug of 100mg*30 tablets produced by a pharmaceutical factory in Laos sells for about 2,000 yuan (the price will vary due to exchange rate fluctuations).